Understanding how AML cells become resistant to therapy over time
Official title: Architecture and Trajectory of Acquired Resistance to Therapy in AML
Funded at Oregon Health & Science University · NIH-11622555 · Data updated 2026-11-12
This project looks at why acute myeloid leukemia stops responding to treatment and how to design better drug combinations to prevent relapse.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | September 30, 2017 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $37,497 |
| NIH project number | 3U54CA224019-09S1 |
| Project ID | NIH-11622555 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with acute myeloid leukemia who are treated with standard or novel therapies and may be candidates for combination strategies in future trials.
✕Less likely to help
Patients not eligible for future combination trials or those with disease biology not addressed by the identified resistance pathways.
What this research studies
Researchers will map the ways AML cells change under treatment and how the bone marrow environment supports those changes. The work builds on a long history of genomic and functional studies in AML, including large datasets and CRISPR screens, to identify when and how resistance pathways emerge. The center collaborates across institutions to translate findings into new clinical trials and practical strategies for patients with AML. The study aims to reveal actionable steps to keep therapies effective longer and improve survival.
Why it matters
Potential benefit: If successful, patients with AML could benefit from more durable responses and fewer relapses through smarter, targeted treatment combinations.
How similar studies have gone: Previous AML research has produced large datasets and several clinical trials guiding combination therapies; this project extends those efforts with an integrated resistance-trajectory approach.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Tyner, Jeffrey Wallace — Oregon Health & Science University
- Study coordinator: Tyner, Jeffrey Wallace
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a protein affects nerve cell movement in Alzheimer's disease
This study is looking at how a protein called APP affects the growth and movement of nerve cells, which is important for understanding Alzheimer's disease, and it aims to find out how problems with this protein might lead to nerve cell damage.
-
Understanding how the bone marrow environment drives AML resistance
A large NIH-funded project at Oregon Health & Science University is studying how the body’s own cell surroundings help acute myeloid leukemia become resistant to treatment, with potential paths to better therapies for patients.
-
Improving Safety at Work with a Low-Resource mHealth Program in Malaysia (and beyond)
A low-cost mobile health program to improve safety culture in Malaysian workplaces, with plans to adapt the approach for U.S. workers in high-risk industries.
-
Oregon Healthy Workplace Initiative for Better Health
A multi-site effort aims to improve the health and safety of workers by coordinating research, tools, and interventions across workplaces.
-
Mechanisms and Countermeasures for Ultra-Potent Synthetic Opioid Overdose
A small, focused NIH grant aims to understand why ultra-potent synthetic opioids cause severe overdose and to explore potential countermeasures to keep people safe.
-
Oregon Spina Bifida Registry Project - Comp B
This grant supports building and refining a national registry to track care practices and health outcomes for people living with spina bifida to improve care and quality of life.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.